Jump to main content
Jump to site search

Issue 5, 2012
Previous Article Next Article

Quantum-dot-based biosensor for simultaneous detection of biomarker and therapeutic drug: first steps toward an assay for quantitative pharmacology

Author affiliations

Abstract

Quantitative pharmacology (QP) is often used to study the recommended dose of a drug. Using colorectal cancer as a model, the relationship between exposure (cetuximab, C225, therapeutic drug of colorectal cancer) and the biomarker response (carcinoembryonic antigen, CEA, biomarker of colorectal cancer) is the core for the QP of C225. Thus, simultaneous detection of CEA and C225 is the first step towards an assay for the QP of C225. We developed a quantum dot (QD)-based multi-analyte biosensor for the simultaneous determination of CEA and the corresponding therapeutic drug C225. The assay is based on the competition between a quantum-dots-labeled glycans and target glycans using lectins as the recognition element. The dual-analytic biosensor detected CEA and C225 in the range from 1 ng mL−1 to 400 μg mL−1 by stripping voltammetry. The biosensor developed here for the simultaneous detection of the biomarkers and therapeutic drugs is expected to develop as a potential technique for quantitative pharmacology.

Graphical abstract: Quantum-dot-based biosensor for simultaneous detection of biomarker and therapeutic drug: first steps toward an assay for quantitative pharmacology

Back to tab navigation

Publication details

The article was received on 25 Sep 2011, accepted on 27 Nov 2011 and first published on 16 Jan 2012


Article type: Paper
DOI: 10.1039/C2AN15894A
Citation: Analyst, 2012,137, 1205-1209
  •   Request permissions

    Quantum-dot-based biosensor for simultaneous detection of biomarker and therapeutic drug: first steps toward an assay for quantitative pharmacology

    C. Yang, C. Xu, X. Wang and X. Hu, Analyst, 2012, 137, 1205
    DOI: 10.1039/C2AN15894A

Search articles by author

Spotlight

Advertisements